Leeds Institute of Clinical Trial research & Leeds Cancer Centre, University of Leeds, Leeds, UK.
College of Myeloma (UK), UK Myeloma Forum, London, UK.
Br J Haematol. 2020 Nov;191(4):542-551. doi: 10.1111/bjh.17148.
The knowledge of disease biology as well as the therapeutic landscape in multiple myeloma (MM) has expanded exponentially in recent years. These advances have seen improvements in survivorship, not only in the clinical trial setting but also in the real setting. Importantly there is also every evidence to indicate that such improvements in our understanding and treatments will continue. This article is not intended to be a comprehensive review; rather it aims to give a temporal context to these developments with exemplars, and highlight the central role that UK clinicians, healthcare workers, scientists and most importantly patients and their relatives have played in this revolution.
近年来，多发性骨髓瘤（MM）的疾病生物学知识和治疗领域呈指数级扩展。这些进展不仅在临床试验环境中，而且在实际环境中都提高了生存率。重要的是，也有充分的证据表明，我们对这些疾病的认识和治疗将继续得到改善。本文并不是一篇全面的综述，而是旨在通过示例为这些进展提供一个时间背景，并强调英国临床医生、医疗保健工作者、科学家，最重要的是患者及其亲属在这场革命中所发挥的核心作用。
